The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NOVN | +27.98% | +52.61% | +8.81% | +810% |
| S&P | +12.9% | +73.65% | +11.66% | +815% |
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.66B | -7.6% |
| Gross Profit | $7.83B | -9.2% |
| Gross Margin | 73.44% | -1.3% |
| Market Cap | $207.97B | 19.8% |
| Market Cap / Employee | $2.76M | 0.0% |
| Employees | 75.3K | -0.8% |
| Net Income | $1.92B | -22.3% |
| EBITDA | $4.05B | -14.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.06B | -12.8% |
| Accounts Receivable | $7.08B | 5.3% |
| Inventory | 5K | -4.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $23.44B | 12.8% |
| Short Term Debt | $4.58B | -39.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 12.37% | 0.9% |
| Return On Invested Capital | 15.00% | 1.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.21B | -62.3% |
| Operating Free Cash Flow | $1.70B | -53.9% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 17.14 | 16.08 | 16.05 | 18.26 | 7.31% |
| Price to Book | 4.84 | 5.55 | 5.80 | 5.96 | 22.86% |
| Price to Sales | 4.22 | 4.08 | 4.21 | 4.67 | 16.32% |
| Price to Tangible Book Value | -27.96 | -15.13 | -19.01 | -25.77 | 16.62% |
| Price to Free Cash Flow TTM | 22.45 | 18.65 | 19.36 | 26.04 | 11.30% |
| Enterprise Value to EBITDA | 41.72 | 43.29 | 48.54 | 56.89 | 39.19% |
| Free Cash Flow Yield | 4.5% | 5.4% | 5.2% | 3.8% | -10.16% |
| Return on Equity | 32.8% | 33.3% | 34.0% | 30.5% | 14.69% |
| Total Debt | $27.67B | $25.98B | $25.48B | $28.03B | -1.06% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
